Truist analyst David MacDonald raised the firm’s price target on Pediatrix Medical to $13 from $10 and keeps a Hold rating on the shares as part of a broader research note on Healthcare Services. The firm is introducing 2026 estimates and 2025 quarterly estimates across several verticals while also adjusting its model estimates on select names, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Questions or Comments about the article? Write to editor@tipranks.com